摘要
According to a Prognoscan database, upregulation of Bruton's tyrosine kinase (Btk) is associated with low overall survival in ovarian cancer patients. We found that spheroids-forming ovarian cancer cell, which highly expressed cancer stem-like cell (CSC) markers and Btk, were cisplatin resistant. We next treated CSCs and non- CSCs by a combination of ibrutinib and cisplatin. We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer.
原文 | 英語 |
---|---|
頁(從 - 到) | 13255-13268 |
頁數 | 14 |
期刊 | Oncotarget |
卷 | 6 |
發行號 | 15 |
出版狀態 | 已發佈 - 2015 |
ASJC Scopus subject areas
- 腫瘤科